Cargando…
A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation of immune complexes. Here, we utilize a versat...
Autores principales: | Goksøyr, Louise, Skrzypczak, Magdalena, Sampson, Maureen, Nielsen, Morten A., Salanti, Ali, Theander, Thor G., Remaley, Alan T., De Jongh, Willem A., Sander, Adam F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864010/ https://www.ncbi.nlm.nih.gov/pubmed/36679847 http://dx.doi.org/10.3390/vaccines11010002 |
Ejemplares similares
-
ABNCoV2-cVLP-based-COVID-2019-vaccine-AdaptVac: Membranous glomerulopathy and diffuse lupus nephritis: 2 case reports
Publicado: (2021) -
IMMUNOLOGIC STUDIES OF ENTERIC CORONAVIRUS-LIKE PARTICLES(CVLP)
por: Lund, Mary E, et al.
Publicado: (1984) -
A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine
por: Janitzek, Christoph M., et al.
Publicado: (2019) -
RNA Phage VLP-Based Vaccine Platforms
por: Peabody, David S., et al.
Publicado: (2021) -
Virus-like particle (VLP)-based vaccines for pandemic influenza: Performance of a VLP vaccine during the 2009 influenza pandemic
por: López-Macías, Constantino
Publicado: (2012)